An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Lung Cancer
Advanced Malignancies
Carcinoma

Interventions

DRUG: Brigatinib

Sponsor

Ariad Pharmaceuticals